BST2 Polyclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-9850R-APC-Cy7-100uL |
| Product Name | BST2 Polyclonal Antibody, APC-Cy7 Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
|
| Reactivity | Human, Mouse |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human BST2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 684 |
| Swiss Prot | Q10589 |
| Subcellular location | Cytoplasm |
| Synonyms | CD317; TETHERIN; Bone marrow stromal antigen 2; BST-2; HM1.24 antigen; BST2 |
| Background | IFN-induced antiviral host restriction factor which efficiently blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. Acts as a direct physical tether, holding virions to the cell membrane and linking virions to each other. The tethered virions can be internalized by endocytosis and subsequently degraded or they can remain on the cell surface. In either case, their spread as cell-free virions is restricted. Its target viruses belong to diverse families, including retroviridae: human immunodeficiency virus type 1 (HIV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency viruses (SIVs), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), prototype foamy virus (PFV), Mason-Pfizer monkey virus (MPMV), human T-cell leukemia virus type 1 (HTLV-1), Rous sarcoma virus (RSV) and murine leukemia virus (MLV), flavivirideae: hepatitis C virus (HCV), filoviridae: ebola virus (EBOV) and marburg virus (MARV), arenaviridae: lassa virus (LASV) and machupo virus (MACV), herpesviridae: kaposis sarcoma-associated herpesvirus (KSHV), rhabdoviridae: vesicular stomatitis virus (VSV), orthomyxoviridae: influenza A virus, and paramyxoviridae: nipah virus. Can inhibit cell surface proteolytic activity of MMP14 causing decreased activation of MMP15 which results in inhibition of cell growth and migration. Can stimulate signaling by LILRA4/ILT7 and consequently provide negative feedback to the production of IFN by plasmacytoid dendritic cells in response to viral infection. Plays a role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |
| IF(IHC-P) | 1:50-200 |
Frequently asked questions
Which applications is BST2 Polyclonal Antibody, APC-Cy7 Conjugated (bs-9850R-APC-Cy7) validated for, and at what dilution?
bs-9850R-APC-Cy7 is validated for WB (1:300-5000); FCM (1:20-100); IF(IHC-P) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does BST2 Polyclonal Antibody, APC-Cy7 Conjugated (bs-9850R-APC-Cy7) react with?
Tested reactivity: Human, Mouse.
How should bs-9850R-APC-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise BST2 Polyclonal Antibody, APC-Cy7 Conjugated (bs-9850R-APC-Cy7)?
KLH conjugated synthetic peptide derived from human BST2
What are the excitation and emission wavelengths of the APC-Cy7 conjugate (bs-9850R-APC-Cy7)?
APC-Cy7 on bs-9850R-APC-Cy7: excitation / emission 650nm/780nm.